Cost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer
Ahmed M. Bayoumi, Adalsteinn D. Brown, Alan M. Garber
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD
Source: Journal of the National Cancer Institute, Volume 92(21): 1731-1739, (November) 2000.
IntroductionAndrogen ablation therapy provides effective palliation for patients with advanced prostate carcinoma. Androgen ablation may be achieved surgically (with bilateral orchiectomy) or pharmacologically, usually with the luteinizing hormone-releasing hormone (LHRH) agonists. Some studies have demonstrated that survival does not differ between patients treated with LHRH agonists and those treated with orchiectomy or diethylstilbestrol (DES) (Ann Intern Med 2000 Apr 4; 132(7): 566-77). However, the side effects and costs of each therapy differ substantially. In this study, the researchers evaluated the cost-effectiveness of androgen suppression in the form of orchiectomy, medication monotherapy, and combined androgen blockade.
MethodThe researchers used a hypothetical man 65 years of age with clinically evident, locally recurrent prostate cancer as their base case. Over a 20-year time horizon they looked at survival, quality-adjusted life years (QALYs) lifetime costs and incremental cost-effectiveness ratios.
- Orchiectomy, with a cost of $7000, had 5.1 QALYs, which resulted in lower costs and higher QALYs than other modalities.
- Androgen suppression therapies were the most cost-effective when patients started treatment early after they became symptomatic from metastatic prostate cancer.